There are four potential outcomes when a patient commences a new drug and its effects are
assessed at the correct time. First, the new drug provides no clinical benefits and gives the …

Pharmacogenomic (PGx) testing of cytochrome P450 (CYP) enzymes may improve the
efficacy and/or safety of some medications. This is facilitated by increased availability and …

Aims Demonstrate the presence of cytochrome P450 (CYP) and UDP‐
glucuronosyltransferase (UGT) proteins and mRNAs in isolated human plasma exosomes …

Although the number of countries participating in pivotal trials submitted to enable drug
registration has nearly doubled over the past 25 years, there has not been a substantial …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately one-third of the global population. Most affected individuals …

Studies that focus on individual covariates, while ignoring their interactions, may not be
adequate for model‐informed precision dosing (MIPD) in any given patient. Genetic …

Healthcare is increasingly fragmented, resulting in escalating costs, patient dissatisfaction,
and sometimes adverse clinical outcomes. Strategies to decrease healthcare fragmentation …

The absolute bioavailability of many small molecule kinase inhibitors (smKIs) is low. The
reasons for low bioavailability are multifaceted and include constraints due to first pass …

Abstract Model-informed precision dosing (MIPD) is modeling and simulation in healthcare
to predict the drug dose for a given patient based on their individual characteristics that is …

Aims This study implements a physiologically‐based pharmacokinetic (PBPK) modelling
approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing …